Nevertheless, in the two leukemia cell lines evaluated in our study, we showed that inhibition of LAT1 further increased the growth inhibitory effects of tunicamycin, in particular post-treatment, i.e. when normal glycosylating conditions were restored. This evidence concerns the gene SLC7A5 and leukemia.